A Cochrane review of three randomized trials involving 126 children with severe hemophilia A evaluated the benefits and harms of initiating clotting factor concentrate prophylaxis before the onset of joint damage. Across the studies, prophylactic regimens were associated with fewer annualized joint bleeds and overall bleeding events compared to episodic treatment, though evidence for improvements in joint protection or quality of life remained uncertain. Follow-up data indicated that while a higher proportion of children receiving prophylaxis showed no joint damage, the certainty of evidence was limited by small sample sizes, heterogeneity, and methodological concerns.
The review found no clear differences between prophylaxis and episodic treatment regarding radiologic joint scores, adverse events, infections, or inhibitor development. Although prophylaxis increased the number of required factor infusions, serious safety concerns were not observed. The authors conclude that prophylaxis offers measurable reductions in bleeding frequencies in previously untreated or minimally treated children, but well-designed future trials are needed to determine its long-term effectiveness on joint function and to evaluate newer therapeutic approaches.